Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups

Anne-Laure Gagez,Émilie Tuaillon,Renaud Cezar,Caroline Dartigeas,Beatrice Mahe,Remi Letestu,Hervé Maisonneuve,Valérie Gouilleux-Gruart,Karine Bollore,Emmanuelle Ferrant,Thérèse Aurran,Patrick Feugier,Stéphane Leprêtre,Guillaume Cartron

Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups

2016

Anne-Laure Gagez
Émilie Tuaillon
Renaud Cezar
Caroline Dartigeas
Beatrice Mahe
Remi Letestu
Hervé Maisonneuve
Valérie Gouilleux-Gruart
Karine Bollore
Emmanuelle Ferrant
Thérèse Aurran
Patrick Feugier
Stéphane Leprêtre
Guillaume Cartron

Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups

Keywords:

Rituximab
Lymphoma
Immunology
Interleukin 10
Leukemia
Stem cell
Hematology
Polymorphism (computer science)
Internal medicine
Medicine
Haematopoiesis
Obinutuzumab
Cancer research
Antibody
Antibody-dependent cell-mediated cytotoxicity

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations